Ibrutinib
- Generic Name
- Ibrutinib
- Brand Names
- Imbruvica
- Drug Type
- Small Molecule
- Chemical Formula
- C25H24N6O2
- CAS Number
- 936563-96-1
- Unique Ingredient Identifier
- 1X70OSD4VX
- Background
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell ...
- Indication
Ibrutinib is indicated for the treatment of the following conditions.
Chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)
Waldenström's macroglobulinemia
Chronic graft-versus-host disease (cGVHD)
Mantle cell lymphoma (MCL)
Marginal zone lymphoma (MZL)
- Associated Conditions
- Chronic Graft-Versus-Host Disease, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma (MZL), Refractory Mantle Cell Lymphoma, Relapsed Mantle Cell Lymphoma, Small Lymphocytic Lymphoma, Steroid-dependent chronic graft-versus-host disease, Waldenström's Macroglobulinemia (WM), Steroid refractory Chronic graft versus host disease
- Associated Therapies
- -
Ibrutinib and Lenalidomide in Treating Patients With Myelodysplastic Syndrome
- First Posted Date
- 2017-12-02
- Last Posted Date
- 2021-10-19
- Lead Sponsor
- Brian Jonas
- Target Recruit Count
- 4
- Registration Number
- NCT03359460
- Locations
- 🇺🇸
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
Pembrolizumab in Combination With Ibrutinib for Advanced, Refractory Colorectal Cancers
- Conditions
- Interventions
- First Posted Date
- 2017-11-06
- Last Posted Date
- 2022-06-03
- Target Recruit Count
- 40
- Registration Number
- NCT03332498
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
A Study of CA-4948 in Patients with Relapsed or Refractory Primary Central Nervous System Lymphoma
- First Posted Date
- 2017-11-01
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Curis, Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT03328078
- Locations
- 🇺🇸
UT Southwestern Medical Center, Dallas, Texas, United States
🇺🇸The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Providence Saint John's Health Center, Santa Monica, California, United States
A Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma
- First Posted Date
- 2017-10-26
- Last Posted Date
- 2024-01-18
- Lead Sponsor
- PrECOG, LLC.
- Target Recruit Count
- 43
- Registration Number
- NCT03323151
- Locations
- 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸University of Kansas, Overland Park, Kansas, United States
🇺🇸West Virginia University, Morgantown, West Virginia, United States
A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies
- First Posted Date
- 2017-10-16
- Last Posted Date
- 2024-04-04
- Lead Sponsor
- Celgene
- Target Recruit Count
- 62
- Registration Number
- NCT03310619
- Locations
- 🇺🇸
Local Institution - 015, Omaha, Nebraska, United States
🇺🇸Local Institution - 016, Philadelphia, Pennsylvania, United States
🇺🇸Local Institution - 011, Duarte, California, United States
A Study to Evaluate the Effect of Ibrutinib on the Pharmacokinetics of Oral Contraceptives, CYP2B6, and CYP3A4 Substrates in Female Participants With B Cell Malignancy
- Conditions
- Interventions
- First Posted Date
- 2017-10-04
- Last Posted Date
- 2019-12-05
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 25
- Registration Number
- NCT03301207
- Locations
- 🇪🇸
Hosp. Univ. Fund. Jimenez Diaz, Madrid, Spain
🇵🇱Pratia MCM Krakow, Krakow, Poland
🇵🇱Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wroclawiu, Wroclaw, Poland
Ibrutinib in Treating Participants With Untreated High Risk Smoldering Mantle Cell Lymphoma
- First Posted Date
- 2017-09-13
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT03282396
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transplant
- First Posted Date
- 2017-08-30
- Last Posted Date
- 2023-08-01
- Lead Sponsor
- Andrew Rezvani
- Target Recruit Count
- 8
- Registration Number
- NCT03267186
- Locations
- 🇺🇸
Stanford University, School of Medicine, Palo Alto, California, United States
Ibrutinib Plus Rituximab and Lenalidomide in Treating Elderly Participants With Newly Diagnosed Mantle Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2017-07-27
- Last Posted Date
- 2019-08-22
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT03232307
Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.
- Conditions
- Interventions
- First Posted Date
- 2017-07-25
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- Pharmacyclics Switzerland GmbH
- Target Recruit Count
- 600
- Registration Number
- NCT03229200
- Locations
- 🇦🇺
Concord Repatriation General Hospital - Haematology Clinical Trials, Sydney, New South Wales, Australia
🇺🇸Emory University, Atlanta, Georgia, United States
🇺🇸The Ohio State University, Columbus, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.